The pepsin trypsin digest of the wheat prolamin gliadin (PT-gliadin) is deleterious to the small intestinal mucosa of coeliac patients. The handling of PT-gliadin by the intestinal epithelium in coeliac patients in remission and control individuals was investigated by in vivo instillation of PT-gliadin. The uptake of PTgliadin was monitored by immunofluorescence microscopy of intestinal biopsy specimens, using affinity purified PT-gliadin antibodies. Control individuals show weak staining in the apical region of the enterocytes thereby showing an uptake of PT-gliadin. Coeliac patients have a conspicuous fluorescence in relation to the lateral membrane/intercellular space of enterocytes and intense staining intracellularly in the apical region. There is only weak staining in the enterocytes after the instillation was terminated, indicating an intracellular clearance. The study shows that normal enterocytes are able to take up PT-gliadin. The increased uptake in coeliac patients might be of importance for the pathogenesis either by direct toxicity or by presentation to immunocompetent cells. Furthermore, the results are in agreement with the suggestion of a functional alteration in the zonula occludens in the intestinal epithelium of coeliac patients.
Coeliac disease is characterised by flattened jejunal mucosa which causes malabsorption. It is well known, that in susceptible individuals, the intestinal mucosal damage is induced by polypeptides in the prolamin fraction of wheat, barley, rye and possibly oats. Complete restoration occurs after a period of prolamin free diet.
Frazer et al' showed in 1959 that a pepsin trypsin digest of the wheat prolamin gliadin (PTgliadin), was deleterious when ingested orally by coeliac patients. The authors used a rise in faecal fat as an objective measure for toxicity. Bramble et al2 supplemented this observation by administering a PT-gliadin preparation directly into the proximal jejunum of adult coeliac patients in remission and controls. The changes in brush border enzymes and morphology were conspicuous within four hours, thereby showing that the mucosal damage, characteristic for coeliac disease, occurred rapidly. The exact toxic component(s) of gliadin has not been identified and the pathogenetic mechanism of coeliac disease remains uncertain.
It is thus well documented that both gliadin and PT-gliadin are toxic to coeliac patients when injested orally. The intraluminal processing of ingested gliadin has only been partly studied, and a difference in the handling of gliadin in coeliac patients and healthy controls has not been demonstrated. It must be presumed, however, that fragments of gliadin are present in the chyme of coeliac patients. Several workers have investigated the breakdown of gliadin at the level of the enterocytes, using homogenates of intestinal biopsies from patients and controls.34 Consistent quantitative differences in the enzymatic activities have not been definitely demonstrated, even though Cornell et al5 did show, that a certain fraction (no 9) of a gliadin digest was less well hydrolysed by enzymes from mucosal biopsies of coeliac disease patients in remission. The capability of a breakdown of gliadin peptides by the intestinal brush border enzymes alone have been studied in detail by Bruce et al.6 It was shown that both brush border from coeliac patients and controls were able to hydrolyse gliadin completely in vitro.
As there is no apparent difference in the digestion of gliadin in coeliac patients and control individuals, there may be a difference in the intestinal uptake and/or intracellular processing of the partly digested gliadin. Gliadin fragments present at the microvillar membrane may be taken up by apical endocytosis. The internalised fragments may subsequently be processed intracellularly and/or be directly toxic in coeliac patients. Optionally, fragments could be transcytosed across the enterocyte and presented at the basolateral membrane for immunocompetent cells, maybe initiating a pathological response in coeliac patients. A pathological route could alternatively be by an intercellular uptake, passing defect tight junctions. In this case, the gliadin fragments may be directly toxic through a binding/uptake via the basolateral membrane. However an in vivo uptake of polypeptides by human enterocytes has so far not been demonstrated.
The purpose ofthe current investigation was to show a possible binding or uptake of PT-gliadin in the enterocytes, and to compare the handling of the components between coeliac patients and controls. The study was carried out by in vivo instillation of PT-gliadin in the jejunum of two control individuals and three coeliac patients in remission. The fate of the PT-gliadin was monitored by immunofluorescence microscopy of intestinal biopsy specimens obtained before, during, and after the instillation, using an affinity purified antibody against PT-gliadin. PT-gliadin was dialysed for 16 hours at 4°C against the coupling buffer (0. 1 mol/l sodium hydrogencarbonate, pH 8-3, 0.5 mol/l NaCl). A total amount of 15 mg protein was coupled to 0-6 g (dry weight) CNBr-activated Sepharose 4B according to the instructions of the manufacturer. The coupled Sepharose was packed in a 1-5 cmx 1.*3 cm column and carefully washed with a 50 mmol/l Tris/HCl, pH 8.0, 0.15 mol/l NaCl buffer.
HUMAN ENTEROCYTE PROTEIN-SEPHAROSE 4B
A biopsy specimen was taken under radiographic control from the jejunum of a healthy individual at the ligament of Treitz. The biopsy was instantly frozen and kept at -80C until further use. The specimen was then thawed at room temperature and homogenised for three minutes on ice in 4 volumes of 50 mmolI1 Tris/HCI, pH 8.0 containing 1% Triton X-100 and 2.8 [ig aprotinin/ml. The homogenisation was performed in a 0-2 ml airfuge tube, using a Teflon pestle, and the homogenate was subsequently centrifuged for one hour at 50 000xg. The protein concentration in the supernatant was determined by use of a microassay version of the Coomassie Brilliant Blue G-250 method,9 using bovine serum albumin as a standard. A total amount of 15 mg enterocyte protein was coupled to 0-6 g (dry weight) CNBr-activatd Sepharose 4B as described above.
RABBIT ANTIBODIES AGAINST PT-GLIADIN Immunisation A 1 mg/ml PT-gliadin solution was prepared by dilution of the gliadin digest with distilled H20 and mixed with an equal amount of Freund's incomplete adjuvant. A rabbit was injected intracutaneously with 400 >d of the solution. After six weeks the rabbit was bled for 10 ml. The immunisation was carried out every four weeks and 10 ml of blood was collected one week after each injection and analysed for reactivity against PT-gliadin by dot blotting.'0 After 42 weeks the rabbit started to produce antibodies against PTgliadin.
Purification
The IgG fraction was isolated from 15 ml rabbit serum on a protein-A Sepharose CL-4B." The PT-gliadin reactive fraction was affinity-purified by using the PT-gliadin-Sepharose 4B column according to the procedure earlier described in detail. '2 In order to eliminate possible antibodies cross reacting with proteins originating from human enterocytes, the purified PT-gliadin immunoglobulin fraction was passed through the human enterocyte protein Sepharose 4B column. The fractions were analysed for reactivity against PT-gliadin and solubilised proteins from human enterocytes by dot blotting.'0 The fractions containing reactivity against PTgliadin only were pooled and stored at 4°C after the addition of sodium azide. The final IgG concentration (0-14 mg/ml) was determined spectrophotometrically from the absorbance at 280 mm. Furthermore, staining could not be observed when the solution of purified primary antibody absorbed with PT-gliadin was used as the first layer (figure not shown).
UPTAKE OF PT-GLIADIN IN CONTROL INDIVIDUALS
PT-gliadin could not be detected before the instillation in normal individuals (figure not shown). During the instillation reactivity was detected extracellulary at the luminal surface. In the sections of intestinal biopsies obtained after 20 ( Fig 2B) and 40 minutes a faint colouring was seen apically in the enterocytes. The staining was homogeneous and without an apparent localisation in granules. There was no difference in the staining between the villous and the crypt regions. Staining could not be demonstrated in relation to the basolateral membrane/intercellular space. After 75 minutes (35 minutes after the instillation was terminated) only very weak intracellular colouring was seen in the two control individuals. Furthermore, the intracellular staining was only observed when the most concentrated immunoglobulin solution (0.07 mg/ ml) was used. The sections incubated with the more diluted antibodies displayed only extracellular staining at the luminal surface of the enterocytes.
UPTAKE OF PT-GLIADIN IN COELIAC PATIENTS
The results ofthe immunofluorescence studies of sections from the intestinal biopsy specimens from coeliac patients are shown in Fig 2A, C-F . There was no staining for PT-gliadin in relation to the enterocytes before the instillation (Fig  2A) . Staining was seen in goblet cells in one of the coeliac patients. This observation occurring in only one patient is thus considered of no importance for the study. lateral membrane/intercellular space of the enterocytes. The staining was most intense in the villous part, but weak colouring also occurred in the crypts. Intense staining was also seen intracellularly in the enterocytes (Fig 2C) . This intracellular fluorescence was located at the brush border region and a granular staining was observed apically within the enterocytes (Fig 3) . The applied immunofluorescence technique, however, did not allow a detailed description of the subcellular localisation of the internalised antigen.
The pattern changed after 40 minutes of instillation (Fig 2D, E) . The subcellular location of the staining was similar but the staining in relation to the lateral membrane/intercellular space and the apical region of the cells was now more intense in the crypt region (Fig 2D) compared with the villous region (Fig 2E) . The last biopsy specimen in the series was taken after 60 minutes, and thus 20 minutes after the PTgliadin instillation was terminated. The staining, which was still most intense in the crypt region, was located in small granules not only near the microvillar membrane, but generally distributed all over the cytoplasm apically for the nucleus (Fig 2F) . A marked staining at the lateral membranes could no longer be observed.
All sections were analysed with the three antibody dilutions. Noticeably, there was no apparent variation in staining intensity between the tested dilutions in the specimens from coeliac patients.
Discussion
The current study clearly shows for the first time that PT-gliadin and/or fragments hereof are present in normal enterocytes after exposure. The PT-gliadin is homogeneously distributed in the apical region of these cells. We have previously performed similar instillation experiments, using undigested gliadin (unpublished results). The gliadin was detected at the microvillar membrane, but an uptake could not be demonstrated. Accordingly, it seems as though only small fragments of gliadin can be taken up, and that an intraluminal digestion of orally ingested gliadin is a prerequisite for the uptake. Even molecules in man under physiological conditions. PT-gliadin can not be detected in relation to the intercellular space in the controls in the currently study and an uptake of PT-gliadin via the tight junctions/lateral membranes therefore seems unlikely in healthy individuals. There are different possibilities as to the fate of the internalised PTgliadin. The staining for PT-gliadin decreases after the instillation is terminated and this might be explained by enzymatic digestion and/or transcytosis.
In contrast to that of normal subjects, the biopsy specimens from coeliac patients show a conspicuous staining at the lateral membrane/ intercellular space after only 20 minutes of instillation. Noticeably, the lateral membrane/ intercellular space staining is more intense in the crypt region than in the villous region after 40 minutes of instillation, and therefore a distinct change from the uptake observed after 20 minutes of instillation. The intracellular staining is intense during the instillation, when compared with normal controls, and still distinct 20 minutes after the instillation is terminated. The lateral membrane/intercellular space staining, however, has vanished after the instillation is terminated. Using electron microscopy, Rubin et al '6 showed that the tight junctions appeared morphologically unchanged in untreated coeliac disease patients. 
